Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam tablets should not require the addition of another antibiotic due to the amoxycillin content of curam tablets.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 1005 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; silicon dioxide; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam tablets should not require the addition of another antibiotic due to the amoxycillin content of curam tablets.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - mebeverine hydrochloride, quantity: 135 mg - tablet, sugar coated - excipient ingredients: purified talc; acacia; gelatin; povidone; magnesium stearate; carnauba wax; potato starch; sucrose; lactose monohydrate - colofac tablets are indicated in the management of the irritable bowel syndrome ( 'irritable colon', 'spastic colon', 'functional bowel disorders', 'spastic constipation', 'nervous diarrhoea'). colofac is used to treat the symptoms of this condition- i.e. abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - isosorbide mononitrate, quantity: 60 mg - tablet, modified release - excipient ingredients: purified talc; titanium dioxide; lactose monohydrate; hypromellose; stearic acid; magnesium stearate; iron oxide yellow; macrogol 4000; carnauba wax; colloidal anhydrous silica - prophylactic treatment of angina pectoris. apo- isosorbide mononitrate 60mg sustained release tablets are not recommended for the management of acute attacks of angina pectoris (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - disulfiram, quantity: 200 mg - tablet, effervescent - excipient ingredients: tartaric acid; magnesium stearate; povidone; maize starch; microcrystalline cellulose; sodium bicarbonate; colloidal anhydrous silica; purified talc; polysorbate 20 - antabuse tablets are indicated as a deterrent to alcohol comsumption and as an aid in the overall management of selected chronic alcoholic patients involved in an integrated program of counselling and psychiatry. only alcoholic patients who are motivated to abstain from drinking and who are undergoing supportive psychotherapeutic treatment, ancillary to a total program of rehabilitation, should be selected for antabuse administration.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; hypromellose; sodium lauryl sulfate; macrogol 6000; purified talc; titanium dioxide - immediate release tablets,isoptin is indicated for:,-hypertension,- angina of effort,- angina at rest,- vasospastic angina (including prinzmetal?s variant angina),- tachyarrhythmias including paroxysmal supra-ventricular tachycardia,- atrial fibrillation with rapid ventricular response,- atrial flutter with rapid ventricular response

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: white beeswax; propylene glycol; magnesium stearate; colloidal anhydrous silica; cellacefate; purified talc; macrogol 20000; povidone; carnauba wax; maize starch; glyceryl monostearate - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: pyralin en tablets are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 180 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; sodium alginate; povidone; magnesium stearate; hypromellose; macrogol 400; macrogol 6000; purified talc; glycol/butylene glycol montanate; titanium dioxide; iron oxide red - modified release tablets,isoptin sr is indicated for the management of hypertension and angina pectoris.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: pregelatinised potato starch; ascorbyl palmitate; magnesium stearate; lactose monohydrate; lactose - ? short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women. ? second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, <> (tibolone tablets) should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at that moment (including cardiovascular disease and breast cancer, see clinical trials and precautions). <> (tibolone tablets) should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: amoxicillin, qty 500 mg; equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxycillin/clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused